Two failed acquisitions have cast a long shadow on Sanofi's prospects.
- Motley Fool•yesterday
Cancer drug costs routinely eclipse the six-figure mark, but the prices of these cancer drugs are truly eye-popping.
- Reuters•5 days ago
PARIS/DAVOS, Switzerland (Reuters) - For the last year, Sanofi's chief executive has made clear his quest for deals to help revive the fortunes of France's biggest drugmaker. Olivier Brandicourt's failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors. In an interview at the World Economic Forum in the Swiss resort of Davos this week Brandicourt defended his track record, citing an unwillingness to overpay for pricey assets and a paucity of good opportunities.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||39.42 - 39.88|
|52 Week Range||36.81 - 44.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.08|
|Dividend & Yield||1.66 (4.12%)|
|1y Target Est||N/A|